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ADDRESSING THE HEART FAILURE EPIDEMIC: FROM MECHANICAL 
CIRCULATORY SUPPORT TO STEM CELL THERAPY 
 
BRITTON B. DONATO 
ABSTRACT 
 At an annual cost of over thirty billion dollars annually, the diagnosis and 
management of heart failure is one of the most significant public health concerns 
of the twenty first century, as nearly twenty percent of Americans will develop 
some form of heart failure in their lifetime. The incidence of newly diagnosed 
heart failure has remained stable over the last several years at approximately 
650,000 diagnoses per year; however, due to several contributing factors the 
prevalence has continued to rise despite substantial advancements in 
interventional therapies. The three most significant contributing factors to the 
rising heart failure prevalence have been identified as 1) significant 
advancements in technology and medical intervention have dramatically 
improved the survival rate of those experiencing acute coronary events. This has 
resulted in a greater number of patients who then progress to chronic heart 
failure. 2) The management of those with chronic heart failure has been 
dramatically improved which has allowed those with the disease to live longer 
and 3) heart failure is in large part a disease associated with advancing age. As 
the population in the United States and other developed countries continue to 
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grow, such a strong association will inevitably result in a rapidly increasing 
prevalence.  
 Current clinically therapies for managing heart failure can be categorized 
into three major groups: pharmaceutical therapy, mechanical circulatory support, 
or cell-based therapy. Pharmaceutical therapies are used in the earlier stages of 
disease progression or to manage symptoms and comorbidities of later stage 
heart failure. Mechanical circulatory support is often implemented when the 
disease progresses to a more severe state, where volume and / or pressure 
overload of the ventricles is present. Many modalities of mechanical circulatory 
support serve as a bridge to transplant, as the only long-term treatment of 
advanced decompensated heart failure is cardiac transplantation. The third 
category of treatments for HF is cell-based or stem cell therapies. These 
therapies are still in their infancies but hold significant potential of cardiac 
regeneration and reversal of the pathologic remodeling associated with heart 
failure.   
 While the management of the early stages of heart failure have improves, 
addressing end-stage failure remains a significant obstacle in resolving the U.S. 
of the heart failure epidemic. The use of ventricular assist devices (VADs) has 
improved the management of end-stage failure over the last few decades, but 
VADs serve mostly as a bridge to transplant, so eventually a donor organ and 
cardiac transplantation is required. As the population continues to grow, the 
number of patients in need of a donor heart will increase, leading to an even 
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larger discrepancy between the number of donor organs available and those in 
severe need. While advancements in VAD technology have reduced potential 
complications and increased the duration and effectiveness of the mechanical 
circulatory support, a long-term permanent treatment is still very much in need. 
 Cell-based cardiac therapy or cardiac stem cell therapy holds the greatest 
potential to solving this age-old problem. The ability to not only regenerate dead 
or damaged tissue in the heart but also reverse pathologic remodeling due to 
heart failure could cure millions of patients of heart failure, returning them to a 
healthy, fully functioning state. The last decade has shed much light on the 
potential of stem cell therapies, but also has illuminated significant barriers to 
creating a clinically acceptable treatment. While these barriers seem tall, it is 
crucial that much time and resources be invested into stem cell therapies for 
cardiac applications as they hold the greatest potential to being able to effectively 
treat, rather than manage, those with heart failure. In addition to regenerating 
dead of damaged myocardium, stem cell technology has the potential to grow an 
entire organ that is patient specific in its origin, and would fully alleviate having to 
wait for an available donor organ. The ability to grow an entire organ in the lab, 
which can later be transplanted, would forever change the way medicine is 
practiced, while saving millions if not billions of lives worldwide.  
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Introduction 
 
 Heart failure (HF) is becoming an increasingly more prevalent public 
health concern, as more than 20% of Americans will develop HF in their lifetime 
(1). According to the Center for Disease Control and Prevention, heart failure is 
listed as the primary cause of 55,000 deaths and a contributing cause in another 
280,000 deaths annually, representing a staggering one in nine mortalities in the 
United States.  Despite medical advances that have improved survival over the 
last several years, the mortality rate for heart failure remains near fifty percent 
within five years of initial diagnosis (2).  The cost associated with the diagnosis 
and management of heart failure is currently exceeding thirty billion dollars each 
year (3), placing further strain on an already struggling U.S. health care system.  
 While the incidence of heart failure has remained relatively stable at 
approximately 650,000 new cases diagnosed per year, the prevalence has 
continued to rise over at an alarming rate (2,4) in large part due to three major 
factors. First, as medical interventions improve, a greater number of patients are 
surviving acute coronary events, which subsequently result in chronic HF. 
Second, treatment for chronic HF has dramatically improved over the last few 
decades, allowing patients to live much longer with the disease. And finally, as 
heart disease is significantly associated with the later stages of life, the aging 
population will inevitably result in an increase in the prevalence of HF (5). 
 Although the prevalence of adult heart failure in the United States may be 
far greater than that of children, pediatric heart failure is also a significant public 
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health concern. Every year, 11,000 to 14, 000 children are hospitalized due to 
heart failure, more than 7% of whom die during their hospitalization. This is quite 
concerning when compared to 0.4% mortality for children admitted to hospitals 
without heart failure. The mortality for children with heart failure also exceeds that 
of adults with the same condition, which is between 3 and 7 percent. Additionally, 
the average hospital length of stay for children with HF increased over 40% from 
1997 to 2006, corresponding to greater than 250,000 total hospital days per year 
(6).  
 In adults, the most common cause of heart failure is ischemic heart 
disease, whose etiology has been well studied and understood. The etiology of 
HF in pediatric patients, however, has been shown to be very different from that 
of their adult counterparts. Dilated cardiomyopathy (DCM) remains the leading 
cause of HF in children older than 1 year of age, and the leading cause of heart 
transplantation in pediatric patients (7,8).  The most challenging aspect of 
treating DCM in children lies in the heterogeneity of its etiology, where 
approximately two-thirds of children diagnosed with DCM are idiopathic (9,10). 
Such a deficit in knowledge likely has contributed to the observations that, 
despite the significant medical advancements, modern therapy has failed to 
improve survival for children suffering from heart failure since the early 1970’s 
(11). Such observations illuminate not only a gap in scientific knowledge with 
respect to the etiology of pediatric heart failure, but also a significant need for 
effective medical therapies to improve outcomes in those suffering from HF.  
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 Current medical therapy for chronic heart failure can be categorized into 
three major groups: pharmaceutical therapy, mechanical circulatory support, and 
cell-based therapy. The specific approach to treating HF is dependent upon the 
severity or stage of heart failure, as well as other concurrently existing diseases. 
For earlier stages of HF, pharmaceutical therapy is often used to treat 
pathologies that are associated with HF such as hypertension, dyslipidemia, 
obesity, and diabetes mellitus (13).  
 For many patients in later stages of heart failure, mechanical circulatory 
support is the most appropriate treatment option, especially when pharmaceutical 
therapy is unsuccessful. Mechanical circulatory support is implemented to reach 
several different outcomes such as bridge to transplant (BTT), bridge to recovery, 
destination therapy, or rescue therapy. 
 Circulatory support is often accomplished by implantation of an 
Extracorporeal Membrane Oxygenation (ECMO) device, which both pumps blood 
for the heart, as well as provides an oxygenation function, or a ventricular assist 
device (VAD) (14). VADs are implantable mechanical circulatory support devices 
that assume the pumping function of the ventricle in which it has been implanted. 
Implantation of left ventricular assist devices occur in approximately 50% of 
patients who are eligible, compared to only 1.5% implantation for right ventricular 
devices. Although left heart failure predominates, there has recently been 
increasing interest in right heart failure and novel assist devices to treat it (15).  
Mechanical circulatory assist devices are currently the best treatment option for 
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those in late stage heart failure, but not without significant risk of adverse events. 
It is clear that novel technologies are required to address the complications that 
accompany current devices, as well as being suitable for right heart failure, 
especially in the pediatric population (14, 16). 
 A lesser developed but potentially powerful therapeutic option for the 
treatment of all stages of heart failure is cell-based therapy. With the discovery of 
cardiac stem cells came the possibilities of regenerative therapies to treat a 
damaged or failing heart. Stem cell therapies for heart failure focus on healing or 
regenerating the functional unit of the myocardium: the cardiomyocyte. By 
stimulating the proliferation of healthy cardiomyocytes, cell-based therapies have 
the potential capacity to return the myocardium to a pre-diseased state. While 
such capability would surely revolutionize the treatment of heart failure, there still 
remains several significant obstacles that researchers must overcome to make 
cardiac stem cell therapy a reality. These obstacles have been categorized as 
improving cell survival, persistence of the stem cells after intramyocardial 
introduction, and proliferation of the introduced cells (17).  
 Following an ischemic event within the myocardium, a cascade of immune 
cells invades the damaged area furthering the tissue damage, as well as 
releasing cytokines that induce native cell apoptosis. Because the stem cells are 
delivered into such a hostile environment, it is not surprising that many of the 
cells do not survive. The most recent approach to solving the survivability issues 
is aimed at reducing the expression of cytokines released from inflammatory cells 
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such as tumor necrosis factor (TNF-α), several interleukins (ILs), matrix 
metalloproteinases (MMPs) and transforming growth factor β (TFG-β) whose 
native role is to regulate cell apoptosis (18). By reducing factors that induce cell 
death, the therapeutic stem cells would be introduced into an environment more 
suitable for survival. Other investigators are proposing that survivability can be 
improved by preconditioning the stem cells prior to injection. While both 
approaches share a common goal, the most effective means to attain 
survivability has not been determined.  
 In addition to survival, the persistence of the stem cells at the delivery or 
injection site must also be improved. When cardiac stem cells were injected into 
the myocardium directly in the mouse model, only 15% of the cells remained in 
the myocardium after one week (19). While a proportion of this problem may be 
attributed to the ischemic environment, the exact cause of the cell disappearance 
is unknown. It is evident, however, that cell persistence is a crucial aspect of 
myocardial regeneration following infarction.  
 In correspondence with the research on improving survival and 
persistence is the search for new or modified stem cells types, which may elicit 
greater cell proliferation. Possible candidates include embryonic stem cells 
(ESCs), induced pluripotent stem cells, and a variety of others (17). While there 
exist many challenges to cell-based regenerative therapy, it promises to be the 
most effective treatment at regenerating functional myocardium and reversing the 
devastating effects of heart failure.  
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The Heart Failure Epidemic 
 To be considered an epidemic, new cases of a given disease must 
substantially exceed the number of expected cases over a specific time frame. 
Although the term epidemic was traditionally reserved for diseases that are 
infectious in nature, the changing public health landscape pushed modern 
epidemiology to also include noninfectious diseases and syndromes like heart 
failure. With a worldwide prevalence of more than 23 million, it is no wonder that 
in 1997 heart failure was specifically singled out as an epidemic requiring 
substantial attention both from a clinical and public health perspective (20, 21).   
 
Definition and Diagnosis 
 The American Heart Association (AHA) and the American College of 
Cardiology Foundation (ACCF) defined heart failure in the 2013 ACCF/AHA 
Guideline for the Management of Heart Failure as a complex clinical syndrome 
that results from any structural or functional impairment of ventricular filling 
ejection of blood. The clinical syndrome of HF may result from disorders of the 
pericardium, myocardium, endocardium, heart valves, great vessels, or certain 
metabolic abnormalities. The most common symptom found in patients with heart 
failure is an impaired or failing left ventricular myocardium. However, this 
impairment of the left ventricular myocardial function is not synonymous with a 
cardiomyopathy or left ventricular dysfunction, as these pathologies would not be 
symptoms of heart failure. Rather, these aforementioned terms provide a 
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pathophysiologic cause for the development of heart failure. The cardinal 
manifestations of such a syndrome are dyspnea, fatigue, and fluid retention. 
Such retention of fluid often results in pulmonary and/or splanchnic congestion as 
well as peripheral edema (22). Diagnosing heart failure can also be challenging 
clinically as most decisions are made from a carefully acquired patient history 
and physical examination. Also, heart failure is not, by definition, a disease. It is 
more accurately a syndrome, or a compilation of observed symptoms that are 
indicative of a single condition, further complicating a successful diagnosis.  
 To make diagnosis of heart failure more manageable for clinicians, several 
criteria have been established. Four of these specific criteria, the Framingham 
criteria, the Boston criteria, the European Society of Cardiology criteria, and the 
Gothenburg criteria, they all share many similar indicators and symptoms and 
elevated filling pressures which are combined with the findings from the medical 
history, physical examination, and imaging (21). Of these criteria, the Boston 
criteria are recommended for diagnostics in older patients because of its ability to 
predict future adverse events (23). The Framingham criteria, which generally 
have a lower positive predictive value for HF diagnosis than the Boston criteria 
but a greater sensitivity, are well suited for secular trends. This is because of its 
ability to maintain a high performance irrespective to time and use of specific 
diagnostic tests (21).  The European Society of Cardiology criteria are likely the 
most objective of the aforementioned criteria. Therefore, in order for these criteria 
to be applied in practice, cardiac dysfunction must be objectively determined to 
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be elevated to a predetermined threshold level or greater, which can often be 
challenging from a clinical perspective (24, 25).   
 The most useful tests for diagnosing heart failure are the 
electrocardiogram (ECG) and the echocardiogram. The ECG is a useful 
diagnostic modality to determine if there are any abnormalities in rhythm or in the 
normal electrical conduction of the heart. The echocardiogram is likely the most 
useful tool for diagnosing heart failure, as it can provide insightful information on 
chamber volumes, end systolic and diastolic volumes, ejection fractions, wall 
motion, and flow dynamics. Knowledge of these aspects of the disease is crucial 
in not only determining the most appropriate treatment, but also in determining 
the etiology of the heart failure (26). 
 In addition to these studies, various biochemical and hematological 
studies are also important in creating the most appropriate treatment plan that is 
tailored to the specific patient. The most important function of these exams is to 
determine renal function and potassium, as they are indicators of whether the 
renin-angiotensin-aldosterone system can be safely modulated with therapy, and 
also to exclude various forms of anemia. As anemia can very closely mimic the 
physical manifestations of heart failure, this is a very important exclusion to make 
before confirming heart failure as a diagnosis. 
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Figure 1: A diagram illustrating the diagnosis of heart failure using various 
diagnostic modalities depending on specific findings (26).  
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 In addition to these studies, a diagnosis and/or etiology is still unclear, 
further testing can be completed. The most common of these examinations 
would be studies such as perfusion imaging, angiography, or endomyocardial 
biopsy (26).  
 
Classifications of Heart Failure 
 Patients requiring hospitalization as a result of HF can present with acute 
decompensated heart failure. The presentation of acute decompensated HF may 
be the result of new onset HF, currently existing HF that is worsening, or 
advanced HF. These patients are experiencing a gradual or rapid change in the 
signs and symptoms associated with HF resulting in the need for urgent 
therapeutic intervention (27). However, not all patients hospitalized for heart 
failure will present with acute decompensated HF, and those that do may not 
always be properly identified and documented. This lack of precise diagnosis and 
documentation places a significant barrier in the way of accurately determining 
the true burden of heart failure and its associated hospitalizations annually. As it 
has been found that many hospitals document nearly all patients admitted for 
heart failure as exhibiting acute decompensated HF, its true burden is likely an 
overestimate as many patients who present with HF as a comorbidity of another 
pathology (21). 
  The broadest classification of heart failure is based upon the left 
ventricular ejection fraction (LVEF). The ejection fraction is the stroke volume, or 
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the volume of blood ejected from the ventricle during one cardiac cycle, as a 
proportion of the end diastolic volume, or the volume of blood in the ventricle just 
before systole. Properly determining a patient’s left ventricular ejection fraction is 
crucial because it will likely influence comorbidities, prognosis, and response to 
specific therapies. The most current guidelines state that if a clinical diagnosis of 
heart failure is made and the ejection fraction is determined to be ≤ 40%, the 
patient is classified as having heart failure with reduced ejection fraction (HFrEF). 
Of these patients, nearly half will also be found to have some degree of left 
ventricular enlargement (22,28,29).  
 Conversely, if a clinical diagnosis of heart failure is made but there is no 
significant reduction in ejection volume (EF is greater than 40%) the patient is 
classified as having heart failure with preserved ejection fraction (HFpEF). 
These patients represent about half of all those clinically diagnosed with heart 
failure (30). Compared to HFrEF, the diagnosis of HFpEF is much more difficult. 
A positive diagnosis would include signs and symptoms of heart failure, evidence 
of a preserved or normal ejection fraction, and evidence of abnormal left 
ventricular diastolic dysfunction, which is determined by Doppler 
echocardiography and/or cardiac catheterization (31).  
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Figure 2: A comparison of the Heart Failure Classification Methods          
(21) 
 
 The most significant cause of HFpEF is hypertension, which is present in 
60-89% of cases (32). Other factors that have been associated with HFpEF are 
obesity, coronary artery disease (CAD), diabetes mellitus, atrial fibrillation, and 
hyperlipidemia (30,33). Ultimately, heart failure with preserved ejection fraction is 
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less understood than its reduced ejection fraction counterpart, thus further 
investigation is necessary better treat this subset of patients.  
 The ACCF and AHA provide further classification by providing criteria for 
stages of heart failure, and the New York Heart Association provides a 
mechanism for functional classification. The ACCF/AHA stages of HF are meant 
to classify the development and progression of disease within an individual or 
population, while the New York Heart Association functional classifiers are used 
to determine exercise capacity and symptomatic status of the disease (22).  
 
Epidemiology 
 It has been estimated that by the year 2050, nearly one in five Americans 
will be older than 65 years of age (13). Because heart disease is most prevalent 
among this age group, the aging population signifies an even greater rise in the 
prevalence of heart failure well into the future. This comes with great concern, as 
the current prevalence of heart failure in the United States alone is already more 
than 5.8 million cases (34,35). In America, the current lifetime risk of developing 
heart failure for those age 40 or greater is 20%, as each year more than 650,000 
new cases of heart failure are diagnosed (36-38).  
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Figure 3: Classification of HFrEF and HFpEF (22) 
 
 Because heart disease is most prevalent among this age group, the aging 
population signifies an even greater rise in the prevalence of heart failure well 
into the future. This comes with great concern, as the current prevalence of heart 
failure in the United States alone is already more than 5.8 million cases (34,35). 
In America, the current lifetime risk of developing heart failure for those age 40 or 
greater is 20%, as each year more than 650,000 new cases of heart failure are 
diagnosed (36-38).  
 The heart failure incidence stratified by age shows significant increases as 
the age group also increases. The incidence rate for individuals between the 
ages of 29 and 79 years is between 1.4 and 2.3 new HF cases per 1000 people 
in the at risk population per year (21,39). However, when looking at individuals 
ages 65 to 69 years of age, the incidence rises approximately 20 new HF cases 
per 1000 people per year. 
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Figure 4: Hospital Discharges for Heart Failure from 1980-2010. The figure 
clearly illustrates a significant increase in the number of discharges for heart 
failure over the last several decades. (https://www.heart.org/idc/groups/heart-
public/@wcm/@sop/@smd/documents/downloadable/ucm_449852.pdf).  
 
 Finally, and most alarming when considering the ever increasing life 
expectancy and aging population, the incidence for those greater than 85 years 
of age is more than 80 new heart failure cases diagnosed per 1000 people per 
year (40). While these national incidence rates have remained relatively stable 
over the last few decades, advancements in the medical technology and 
treatment has attributed to the rapidly increasing prevalence of heart failure both 
in the U.S. and abroad. While these national incidence rates have remained 
relatively stable over the last few decades, advancements in the medical 
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technology and treatment has attributed to the rapidly increasing prevalence of 
heart failure both in the U.S. and abroad. 
 
 
Figure 5: The age and gender stratified prevalence of heart failure, as a percent 
of the population at risk (https://www.heart.org/idc/groups/heart-
public/@wcm/@sop/@smd/documents/downloadable/ucm_449852.pdf). 
 
 With respect to mortality rates, the five and ten year survival following the 
initial diagnosis of heart failure is 50% and 10%, respectively (21). While a five-
year survival rate of 50% is considered poor at best, it is a marked improvement 
in comparison to the 30-40% 5 year survival rates observed before the 1990s 
(26). Like mortality rates, the hospitalization rates as a result of heart failure have 
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also declined over the past decade. The largest study to date examining 
temporal trends in hospitalization rates from HF using the Medicare database 
indicated that from 1998 to 2008 there was a relative decline of 29.5% in risk-
adjusted HF hospitalization rate (41). This decline has been attributed to fewer 
unique individuals hospitalized for heart failure, yet considering that 
advancements in HF care have improved survival, a decrease in hospitalizations 
is quite surprising.  
 One would expect longer survivals to result in a greater number of 
rehospitalizations and an overall increase in hospitalization rates compared to 
those in 1998, but this was not the case. This lack of an increase, when 
considering the average hospitalization cost for heart failure of $18,000 per 
patient, represents a saving solely due to heart failure hospitalization in 2008 of 
4.1 billion dollars in fee-for-service Medicare. It should also be noted that this 
study also demonstrated substantial geographic variation for both heart failure 
hospitalization and one-year mortality rates. Such a variation represents 
significant and undeniable differences in outcomes that cannot be explained by 
insurance status (41).  
 While the evidence supports the notion that we are moving in a positive 
direction with respect to addressing the heart failure epidemic, there are many 
significant hurdlers that must be overcome in order to truly make a significant 
difference. One of those hurdles is addressing those that are already in 
advanced end-stage heart failure. The majority of these patients will no longer 
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benefit from pharmacological therapy. The gold standard for patients at this stage 
of HF is undoubtedly heart transplantation, which has been proven to elicit good 
long-term survival post-operatively. However, as the number of patients with 
advanced heart failure continues to rise, the limited number or hearts available 
for transplant falls vastly short of demand, leaving thousands of patients 
searching for viable alternatives.  
 The most effective alternative to transplantation is mechanical circulatory 
support (MCS) therapy, and more specifically, ventricular assist devices or VADs 
(McMurray). Looking into the future, it is likely that patients in end-stage heart 
failure will have two options if transplants are not available. The first being more 
highly developed mechanical circulatory support devices, and the second being a 
cell-based therapy. While cell-based therapies are merely in their infancies today, 
they possess the potential to replace injured or dead cells, even organs, with 
new, properly functioning ones. The future looks bright as the potential of both 
technologies promise to ease the burden of HF and improve the lives of millions 
of people around the world plagued by heart failure.  
 
Current Technology: Treating Heart Failure 
 The ultimate goal when treating patients who have been diagnosed with 
established heart failure is to improve survival while also bettering their quality of 
life by relieving as many of the resultant symptoms as possible. Such an 
approach has additional benefits of reducing hospital admissions and 
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readmissions due to heart failure, which is beneficial both for the patient and the 
healthcare system (42). The initial treatment plan for those suffering from HF is 
usually pharmaceutical therapy. Many of these therapies have been shown to 
effectively relieve many of the symptoms of HF, which then lead to a greater 
quality of life, higher functional capacity, and better survival. Cardiac 
Resynchronization Therapy (CRT) is also a more primary treatment option for 
HF, and often has the same many of the same benefits as pharmaceutical 
therapies. In addition to treating HF and its symptoms, therapies aimed at 
treating the various comorbidities of heart failure are also a crucial aspect in 
providing the best possible care for patients. Comorbidities are important to 
consider because they may influence the pharmaceutical therapies available to 
specific patients, and their existence is strongly associated with poorer 
prognoses. Clinicians must, therefore, closely monitor and manage the various 
comorbidities associated with heart failure for each patient, and strongly consider 
him or her when making decisions with respect to the best possible treatment 
plan (26). However, when the aforementioned treatment options fail to be 
effective and the patient’s status continues to decline, many clinicians will turn to 
mechanical circulatory support or transplantation. While these treatment options 
may accompany greater risk, as at this point in the disease pathway, there are 
few other options.  
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Non-Surgical Device Treatments:  
 The most common treatment modalities, which are much less invasive 
than mechanical circularity support devices, are the implantable cardioverter 
defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT). Both of these 
treatment options act by regulating and modulating the electrical signals of the 
cardiac cycle to either prevent or treat arrhythmias. As nearly half of all deaths in 
patients diagnosed with heart failure are due to a ventricular arrhythmia, 
preventing such deadly arrhythmias is a principal goal in improving survival in 
these patients. In addition to ICD and CRT, several new technologies are being 
developed using similar principles such as implantable cardiac monitors and 
wearable defibrillator vests (26,43).  
 An implantable cardioverter defibrillator (ICD) is a small device that is 
implanted in the body and has leads that are placed near the patient’s heart. The 
leads of the ICD carry electrical current that acts to both provide a normal pacing 
of the heart as to maintain normal sinus rhythm, as well as having the capability 
of high energy cardioverting/defibrillation discharges. These allow the heart to be 
resynchronized in the event of dysrhythmia to restore normal cardiac rhythm 
(44). The original ICD devices developed were quite large in size, and required a 
pocket for implantation of the body of the ICD into the abdomen, as well as a 
thoracotomy to place the leads onto the surface of the heart. Technological 
advances have now allowed for the production of much smaller transvenous 
pectoral devices. These advances have markedly reduced the likelihood of 
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complications as a result of device implantation, as well as improving 
functionality and monitoring capabilities, all of which have improved patient 
survival by dramatically reducing the incidence of sudden cardiac death in 
patients with heart failure. (45). 
 
 
 
Figure 6: Depiction of the placement of an implantable cardioverter defibrillator 
(ICD). Image courtesy of Munson Medical Center. 
(http://www.munsonhealthcare.org/?id=1321&sid=2) 
 
 A second treatment modality that utilizes electrical stimulation is cardiac 
resynchronization therapy. In patients that have discoordinate wall motion due to 
delays in the native conduction system of the heart, CRT can be highly effective.  
These patients with discoordinate contraction of the lateral walls are a different 
subset of heart failure patients than those with fixed functional defects. Identifying 
this subset of patients can be done using electrocardiography (ECG). Because 
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these patients have a delay in the native electrical conduction through the 
ventricles causing the discoordinate contraction, a widened QRS interval would 
be present, particularly an LBBB-type morphology (46). Of all patients presenting 
with heart failure, approximately one quarter of them will have a widened QRS 
interval. Compared to patients who don’t have widening, patients who do are 1.7 
times more likely so experience worsening heart failure and sudden cardiac 
death (47), giving these patients with discoordinate contraction among the worst 
prognosis and underlying left ventricular dysfunction of all heart failure patients.  
 Recently it has been shown that the discoordinate wall motion alone is an 
independent predictor for worsening heart failure regardless of QRS interval 
duration. In a study done by Bader et al., ventricular free wall dyssynchrony that 
was diagnosed using tissue Doppler imaging conferred a significant reduction in 
event free survival and experienced much worse outcomes (48). The intuitive link 
between an electrical delay in the conduction system and a resultant 
discoordinate mechanical wall motion is relatively simple to explain in a healthy 
heart. However, in a diseased heart, especially a failing one, this link becomes 
substantially blurred.  
 Effective cardiac resynchronization therapy can very quickly resynchronize 
a previously dyssynchronous ventricular contraction, which subsequently 
enhances systolic cardiac function (46). Many of the therapies aimed at treating 
end-stage heart failure, like ventricular assist devices, do so by improving the 
ventricular ejection fraction. Not only does an increase in ejection fraction provide 
 23  
a greater cardiac output for the rest of the body, it also dramatically reduces the 
burden of a pressure or volume overload of the ventricles.  
 
 
 
Figure 7: A Depiction of the lead placements for a Cardiac Resynchronization 
Device (51) 
 
 CRT is able to improve the ventricular ejection fraction, doing so without a 
marked increase in the metabolic demand of the myocardium, by significantly 
improving the efficiency of the chamber (49). In addition to an improved ejection 
fraction and cardiac output, patients with longer-term use of CRT also experience 
a reduction in both end-diastolic volume (EDV) and end-systolic volume (ESV). 
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The ultimate effect of these changes is creation of a cardiac environment that is 
conducive to a reversal of the pathogenic cardiac remodeling (46,50).  
 Cardiac resynchronization has been shown to be highly effective at 
reducing clinical symptoms and improving survival in patients with 
dyssynchronous contraction and electrical conduction delays as well as allowing 
for a reversal of deleterious cardiac remodeling from chronic failure. By 
combining CRT with an implantable cardioverter defibrillator, an even greater 
improvement in survival is observed. This is likely due to the prevalence of 
arrhythmia in patients with dyssynchronous wall motion and heart failure, 
allowing the effective treatment of both life-threatening events.  
 
Mechanical Circulatory Support 
When patients fail to respond to pharmaceutical interventions, cardiac 
resyncchronization therapy (CRT) has been shown to improve symptoms, reduce 
hospitalizations, promote deleterious remodeling, and decrease mortality. 
However, there still exist many challenges in identifying the ideal candidates for 
CRT, and it has not proven to be effective for patients in end-stage refractory 
heart failure (51). End stage refractory HF is defined as exhibiting symptoms at 
rest or upon minimal exertion of profound fatigue, inability to perform most 
activities of daily living, requirement of repeated or prolonged hospitalizations for 
intensive management, or evidence of refractory cardiogenic shock (52).  
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Figure 8: Implantable Cardioverter Defibrillator and Cardiac 
Resynchronization Therapy Combination (46) 
(A):  A comparison of all-cause mortality between patients who received cardiac 
resynchronization therapy (CRT) alone, CRT in concert with defibrillator, and no 
treatment. The data shows a significant decrease in mortality for those who 
received CRT + defibrillation compared to controls, and a borderline 
improvement for CRT alone. (B):  A comparison of outcomes in patients 
receiving Implantable Cardioverter Defibrillator (ICD) vs placebo and those taking 
Amiodarone, a pharmaceutical treatment used for treating cardiac arrhythmias, 
versus placebo based on mortality rate. 
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For these patients, cardiac transplantation remains the most effective 
treatment, however, a significant shortage of donor organs, and the fact that 
many patients are poor candidates for transplantation, leaves many patients 
looking for alternative treatments (53).  
 
Ventricular Assist Devices (VADS) 
For these patients who find themselves unfit for cardiac transplantation, 
mechanical circulatory support can be a viable option as a bridge to 
transplantation for those on a wait list, destination therapy for those unsuitable for 
transplantation, or bridge to recovery. Mechanical circulatory support is defined 
as using a mechanical device to assist or replace the hearts ability to adequately 
circulate blood throughout the body (54).  The most extensive of these devices 
are the ventricular replacement devices, which act as total artificial hearts 
(TAHs), who do not act to assist the natural heart, but to perform the task of 
pumping blood unassisted by native heart contraction (55).  More common, and 
more developed are the ventricular assist devices (VADs). There currently exist 
VADs, which can be implemented for the left ventricle, known as LVADs, the 
right ventricle, known as RVADs, or both ventricles, known as BiVADs.  
The first developed mechanical circulatory support device became 
available in the 1960's, which was an extracorporeal left heart bypass pump. 
While its success may not have been ideal, it inspired successful implantation of 
a pneumatically driven total artificial heart by the mid 1980's (56,57). Throughout 
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the following decade, much interest was sparked in the development of 
ventricular assist devices, rather than total artificial hearts, as they could serve as 
a viable bridge to transplant for many severely ill patients.  By 1992, it had been 
shown that even early LVAD technology increased survival to transplant by at 
least 15% compared to patients receiving other medical therapies (58,59), and 
two years later, the first LVAD, which used an external power source, was 
approved by the FDA for bridge to transplant applications (60).  
At the turn of the century, VADs had yet to be approved for anything other 
than bridge to transplant. This is hardly surprising as the second leading cause of 
death for those that had undergone VAD implantation was device failure, 
preceded only by sepsis, as the one and two year survival with LVAD support 
was 52% and 23%, respectively (61). Despite the complications, the LVAD 
HeartMate VE was approved by the FDA for destination therapy in 2003 (51). 
In the ten years following the approval of HeartMate VE, significant 
advancements have been made in ventricular assist device technology. The vast 
majority of current ventricular assist devices employ highly efficient rotary pumps. 
In fact, many VADs are classified by the type of flow the pump provides, as well 
as other technical aspects. The first generation pumps are pulsatile, thus the 
device acts to pump the blood in a pulsatile fashion in an attempt to mimic the 
hearts natural pumping mechanism. These pulsatile pumps can work either in 
synchrony with the native heart, or in a counterpulsation manner. The second 
and third generations of VADs are continuous flow rotary pumps, which operate 
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at a constant flow rate, and can be further classified as axial, centrifugal, or 
mixed flow. Separating the second and third generation of continuous flow 
pumps is the use of bearings in the second-generation devices, which are in 
constant contact with the blood. Such contact dramatically increases the risk of 
thrombotic events, among other complications. The most current, third 
generation devices, have achieved a contactless bearing system through 
magnetic or hydrodynamic suspension, which reduces the probability of 
thrombotic events, but at the cost of increased control complexity and power 
consumption (55).  
 
Surgical Implantation of VADs 
The surgical implantation of ventricular assist devices has not significantly 
deviated over the last several years. Implantation requires a median sternotomy 
followed by inflow and outflow cannulation. Inflow cannulation is made at the left 
ventricular apex, and outflow cannula is anastamosed to the ascending aorta, 
usually via a Dacron graft. A single driveline exits the abdomen to the power 
supply and controller (62).  
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Figure 9: Depiction of an implanted HeartMate II Left Ventricular Assist Device 
(62) 
 
 
Pulsatile Versus Continuous Flow Ventricular Assist Devices 
For patients in late stage advanced heart failure, continuous flow 
ventricular assist devices have become the standard of care. Their small size 
and durability offer a number of significant advantages and reduce the likelihood 
of post-implantation complications (63).  Many first generation pulsatile flow 
devices are much larger in size and weight compared to their continuous flow 
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counterparts, as well as lacking the ability to operate silently without vibration. 
Pulsatile pumps are also used most frequently for short to medium duration 
circulatory support, as complications have long prevented extended support. 
Therefore, the design objective of the continuous flow devices was to provide 
extended circulatory support for patients in advanced heart failure. These 
devices consist of an internal continuous flow rotary pump, which is 
percutaneously connected to an external controller and power source. While the 
percutaneous lead comes with a risk of infection, this risk has been reduced in 
comparison to previous generations of ventricular assist devices (63). 
The most significant feature that accompanies the continuous flow rotary 
pump devices is the continuous unloading of the ventricle throughout the entirety 
of the cardiac cycle. In comparison, pulsatile pumps in synchrony with the native 
heart are only able to unload the ventricle during systole. As pressure and 
volume overload of the ventricles often result in the progression of a failing heart, 
the ability to reduce the burden of either pressure or volume overload by 
continuous ventricular unloading has proven beneficial. Although continuous flow 
pumps virtually eliminate an arterial pulse, there appears to be no significant 
physiologic consequence (64), apart from the difficulties of attaining a routine 
blood pressure measurement (63), leaving the weight of its benefits far greater 
than that of its flaws.  
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Figure 10: A comparison of the inner mechanics between the pulsatile-flow 
LVAD (a, left) and the continuous-flow LVAD (b, right) (51) 
 
 
Both continuous centrifugal flow and axial flow devices share a common 
simplicity of design: a single moving component. This component, termed an 
impeller, rotates within the pump, propelling the blood forward. The internal 
bearings that allow rotation of the impeller can be blood immersed, 
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hydrodynamically suspended, or magnetically levitated, all three of which exhibit 
very little or absent friction, heat generation, and physical wear, making them 
ideal candidates for extended circulatory support (65-67). Efficacy of the 
continuous flow devices was further improved through the elimination of a 
reservoir chamber and inflow/outflow valves, reducing the blood contact surface 
area. Additionally, the blood contact surfaces that remained were designed with 
specialized textured titanium to further minimize the thrombogenicity of the 
device (68).   
 
 
 
Figure 11: Comparison of the attributes of pulsatile and Continuous flow VADs 
(63). 
 
 33  
The Potential of Cardiac Stem Cell Therapy for Treating Severe Heart 
Failure 
 While medical technology has taken significant strides forward over the 
last several decades, patients in end-stage heart failure still are quite limited in 
their therapeutic options. When pharmaceutical therapy begins to fail, many 
patients are left with little choice, mainly mechanical circulatory support by means 
of ventricular assist devices. While these devices have dramatically improved 
outcomes, they still accompany significant risk of adverse events. In the future, it 
is vital for researchers to improve the efficacy of these devices while making 
them smaller and less invasive. It is also crucial that the significant risk of 
adverse effects be addressed. When considering the most effective treatment for 
those in end-stage heart failure is transplantation, improving the ventricular assist 
technology will allow a greater number of people to survive long enough to 
receive a transplanted heart.  
 However, as the population continues to grow, and the prevalence of heart 
failure remains high, it is inevitable that the number of patients requiring 
transplant will significantly outweigh the number of organs available. With this in 
mind, it is clear that the most effective treatment would be one in which the 
patients own heart, and own cells, could be regenerated to a healthy state. The 
recent discovery of cardiac stem cells has made such a treatment a possibility, 
even in the near future. From an injection of stem cells that regenerate a specific 
infarcted area of the heart, to growing an entirely new organ in the lab that can 
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later be transplanted into the patient, the possibilities of cardiac stem cell therapy 
seem endless.  
 
Regenerative Properties of the Heart 
 For many years, the heart has been considered a terminally differentiated 
postmitotic organ without capacity for myocyte regeneration. Research dating as 
far back as 1850 suggested that myocardial hypertrophy was the result of 
hyperplasia and hypertrophy of existing cardiac myocytes (69). The increase in 
weight of the heart, as observed from birth to senescence or in cardiac disease, 
was the consequence of equivalent increases in cardiomyocyte cell size. This 
widely accepted paradigm, therefore, implied that cardiomyocytes persist 
throughout one’s entire life, making them immortal in both their structure and 
function. However, this assumption of cell immortality seemed to contradict the 
modern concept of cell aging and programmed cell death by apoptosis. It has 
been determined that cardiac myocytes do indeed undergo apoptosis, yet for this 
to be plausible, myocytes must possess the ability to replace lost cells, or the 
organ itself would cease to exist far before what is regularly observed (70).  
 Evidence suggesting the presence of cardiac stem cells capable of 
maintaining homeostasis of the myocardium was supported by the discovery of 
high levels of cardiac chimerism as a result of the migration of primitive cells from 
a male heart transplant recipient to the grafted heart he received, whose donor 
had been female. Because the transplants were sex mismatched, the presence 
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of a Y-chromosome in cells within the cardiac allograft indicated that those cells 
had migrated to the female heart and given rise to cardiac cell progenies. This 
observation brought to light the possibility that the Y-Chromosome-positive cells 
within the female heart were either the progeny of primitive cells of the bone 
marrow, or the result of differentiated stem-cell like cells that migrated to the 
allograft from cardiac remnants. These cells were found to express c-kit, MDR1, 
and Sca-1 (71, 72) which are stem cell-related antigens found in stem cell 
populations of the bone marrow, brain, skeletal muscle, and heart. Specifically, 
cardiac stem cells are undifferentiated, lineage-negative cells that are self-
renewing, clonogenic, and capable of differentiating into mature progenies both 
in vitro and in vivo (73).  
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Figure 12: Histological slides of various tissues of the Heart including cardiac 
myocytes, smooth muscle cells, endothelial cells, neural cells, and fibroblasts. In 
A, the green fluorescence indicates the presence of c-kit.  In B, the purple 
fluorescence indicates the presence of MDR1. The yellow fluorescence in C 
indicates Sca-1 reactive protein. The remaining cells were used as controls. 
(Scale bars = 10 microns.)  
(http://www.pnas.org/content/suppl/2003/08/20/1832855100.DC1/2855Fig9Lege
nd.html) 
 
 
 Further supporting the hypothesis that the cells of interest were not fully 
differentiated were blatant discrepancies in the volume of the cells in mitosis 
before cytokinesis. A fully mature cardiac myocyte has an approximate volume of 
25,000 µm3. If the cell were to be fully differentiated, it must expand its volume in 
mitosis before cytokinesis to approximately twice that of its original volume 
(50,000 µm3) in order to give rise to two symmetrically divided, identical cells. 
Observation of the replication of human cardiomyocytes in mitosis revealed that 
their volumes differed markedly from expected values with volumes ranging from 
less that 1,000 µm3 to a maximum observed volume of 5,000 µm3. This irregular 
behavior of mitotic cells suggests progressive differentiation. (74-76). It was this 
discovery, evidence indicating that the mechanism of myocyte formation differs 
substantially from what would be expected of nondifferentiating cells, along with 
the identification of cells with male origin within the myocardium of a female 
heart, which provided the foundation for the identification and characterization of 
cardiac stem cells in the adult myocardium (73).   
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Myocardial Progenitor Cells 
 
 As the study of cardiac plasticity and myocardial regeneration continues to 
expand, so does the variety of stem, precursor, and progenitor cell lines present 
within the myocardium. The first of these cells to be discovered was the c-kitPOS 
stem cell. Following its discovery was the recognition of several other progenitor 
cells including ISL1 progenitor cells, epicardial progenitor cells, side population 
progenitor cells, Sca1 progenitors, and the recognition of progenitor cells forming 
a complex structure known as a cardiosphere. It has recently been shown that 
the c-kitPOS CSCs play the most significant role in the generation of myocytes, 
vascular smooth muscle cells, and endothelial cells following injury as the result 
of an infracted myocardium. Cardiomyocytes that are the progeny of c-kitPOS 
CSCs have also been shown to acquire all of the appropriate mechanical and 
electrical properties of a fully functioning, mature  
Myocytes (77-80). Therefore, its emergence in a previously infarcted ventricular 
myocardium is associated with improvements in ventricular function (79, 80). 
The LIM-homeobox transcription factor islet-1 (ISL1) marks one of two 
specific pools of cardiac progenitors originating from the embryonic cardiogenic 
plate. ISL1+ cells represent the second lineage of cells located more dorsal and 
medial in the cardiogenic plate, with a unique, delayed, migratory path. 
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Figure 13: The Cellular Distribution and Function of Stem Cell Associated Cell 
Surface Markers (http://www.hmc.org.qa/en/) 
 
 These cells migrate into the developing heart from dorsal positions at the 
anterior and posterior poles (81-83). This lineage of cells will become the major 
source of cardiac progenitors that ultimately form the outflow tract, the right 
ventricle, portions of the left ventricle, and the atria (84).  
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Figure 14. The Various Origins and Classes of Stem Cells for Cardiac Therapy 
(94) 
 
Therefore, ISL1+ progenitor cells from the second heart field account for 
all three lineages of cells within the heart; endothelial cells, smooth muscle cells, 
and cardiac muscle cells. While it has been explicitly demonstrated that ISL1+ 
cells play a pivotal role in the developing heart, and do in fact account for a 
substantial portion of cardiac progenitors during cardiac development, their ability 
to serve as a postnatal stem cell appears to be negligible (80). More research 
must be completed to determine the effectiveness of using ISL1+ cells for 
therapeutic cardiac regeneration.  
 
 Classification of Cardiac Stem Cells and Progenitors 
 Piero et. al., 2006, proposed a means of classifying the various immature 
cells within the heart on the basis of their relative differentiation (73). These four 
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classes are: cardiac stem cells (CSCs), progenitors, precursors, and amplifying 
cells. CSCs are the most primitive, and all sequential classes are progressively 
more differentiated. Additionally, CSCs, progenitors, and precursors all express 
c-kit, MDR1, and Sca-1 antigens, while the amplifying cells fail to express any of 
the aforementioned cell surface antigens (73). Differences in the expression of 
CSC surface antigens have dramatic implication on the development of the cell, 
thus a thorough understanding of this concept must be attained in order to create 
the most beneficial cardiac stem cell therapy. 
 It has also been found that CSCs are negative for the expression of 
hematopoietic and endothelial antigens CD45, CD34, CD31, and KDR. CD45 
and KDR surface markers are typically present on c-kitPOS cells that originate in 
the bone marrow and migrate to the heart following myocardial injury. Therefore, 
the absence of CD45 and KDR surface markers in a population of hCSCs 
indicates that these cells do in fact originate from stem cell niches within the 
myocardium (72,79). Upon activation, these cells will divide symmetrically, as 
well as asymmetrically ultimately giving rise to fully differentiated, lineage-
negative cells. This evidence strongly supports the existence of a linear 
relationship between human cardiac stem cells and the formation of mature, fully 
differentiated myocytes (79). Refuted, therefore, is a mechanism of 
dedifferentiation of mature myocytes resulting in the formation of a pool of 
cardiac stem cells.  
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Side Population Cells 
 The existence of a resident pool of myocardial progenitors was first 
determined due to the presence of an ATP-binding cassette transporter protein 
which gave the stem cells the ability to expel Hoechst dye and other toxic 
compounds (85). The side population hematopoietic cells were among the first 
class of myocardial progenitors to be identified, as a result of their P-glycoprotein 
Abcg2 transporter activity, as well as the later discovered Mdr1 (77,79). It was 
also observed that the population of side population cells residing in the mouse 
model was noticeably depleted following infarction, indicating that the side 
population cells were being committed to the myocyte lineage (85).  
 Although the investigators failed to identify a cardiac stem cell throughout 
their studies, it should be noted that they effectively documented a myocardial 
stem cell response following ischemic injury to the heart, introducing the concept 
of resident cardiac stems cells and cardiac regeneration. It was later determined 
that the side population cells primarily generate vimentin-positive fibroblasts and 
calponin-positive smooth muscle cells in response to myocardial injury, and that 
only a small fraction of the side populations cells contribute to the myocyte or 
endothelial cell lineages (86). 
 Side population cells comprise 2% of the cardiac cells in a mouse model. 
They are Sca1high, c-kitlow, CD34low, and CD45low. The major determinant of the 
side population phenotype is Bcrp1, however, their exists Bcrp1 cells that are 
both positive and negative for CD31. Those cells that are Bcrp1 and CD31 
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positive are found within the intima of the vessel wall. Bcrp1 positive cells that 
are negative for CD31 are very different from those that are CD31NEG, and also 
express CD29 and N-Cadherin at the interface between the myocytes and 
adjacent smooth muscle cells. These cells were found to exist in the perivascular 
regions well as the myocardial interstitium (77). The most recent data indicates 
that the only class of cardiac side population cells with a high cardiomyogenic 
potential is the Sca1POS CD31NEG subset. This unique subset of cardiac side 
population cells possess the ability to differentiate into fully functional adult 
myocytes (87). 
 Interestingly, the expression of Abcg2 that regulates the proliferation of 
cardiac side population cells has also been implicated in the proliferation of 
cancer cells. Therefore, as new chemotherapies that specifically target Abcg2 
are introduced, we must be conscious of the significant potential of resultant 
cardiac toxicity as a side effect (87). 
 
Epicardial Progenitors 
 The epicardium, also known as the visceral pericardium, has been 
identified as source of cardiac progenitor cells. The embryonic fetal epicardium 
hosts a variety of progenitor cell classes, providing the capacity to participate in a 
variety of previously unknown functions. Most relevant to cardiac regeneration, a 
population of proepicardial Tbx18-positive progenitor cells is thought to give rise 
to a substantial fraction of cardiomyocytes embryologically (88).   
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 Importantly, a pool of c-kitPOS cells has been discovered in the epicardium 
of the human heart. Following ischemic insult, the c-kitPOS CD117-positive cells 
accumulate in the subepicardial space and later migrate across the subepicardial 
space or myocardium to the region of the heart that has been damaged and is 
likely undergoing regeneration (89). After migration, the c-kitpos cells differentiate 
into myocyte precursors and vascular cells. Therefore, it is likely that these cells, 
originating from the postnatal epicardium, play a role in cardiac regeneration 
following injury (90). 
 
Cardiospheres  
 A significant challenge in producing a clinically useful cardiac stem cell 
therapy is the expansion of progenitor cells retrieved from the human heart. An 
increasingly effective approach to this problem is the direct growth of 
endogenous cardiac progenitor cells from percutaneous endomyocardial biopsy 
specimens as spherical aggregates termed cardiospheres (91,92).  These 
cardiospheres consist of several distinct layers. The core of the sphere consists 
of c-kitPOS, Ki67+ proliferative cells that have a cardiac progenitor 
immunophenotype, as supported by the expression of stem cell and 
cardiomyocyte-related antigens (92). 
 More superficial to the cardiosphere core are several layers of increasingly 
differentiated cells expressing cardiomyocyte proteins and connexin 43. It has 
been shown that the expression of connexin 43 promotes various cell fates 
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depending on the level of differentiation of the cell. Expression on 
undifferentiated progenitors favors their proliferation, whereas expression on 
cells that have already been committed to the myocyte lineage will promote 
electrical coupling with cells in its direct vicinity, and subsequent acquisition of 
functional competence. As these cells develop, they form gap junctions with less 
differentiated cells, thus the connexin 43 positive differentiated cells likely play a 
supportive role for the undifferentiated cells within the cardiosphere. Finally, the 
outermost layer of the cardiosphere is composed primarily of mesenchymal 
stromal cells (80). 
 Therefore, when cardiac progenitor cells are directly cultured from cardiac 
tissue, the formation of cardiospheres creates a unique, niche-like environment 
allowing for vast proliferation of cardiac progenitors within its core, as well as 
surrounding layers of early committed cells that may enhance the viability of 
cardiosphere-derived therapy to regenerate the myocardium and improve cardiac 
function following infarct (91,93). 
 
Clinical Applications of Cardiac Regeneration 
 While the causes of heart failure are vast in origin, each and every one 
ultimately results in injury or death to the cardiomyocytes, impinging on their 
ability to function effectively. As the cardiomyocytes begin to lose functionally,  
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Figure 15. The classes of Cardiac stem cells and progenitor cells. 
Schematic representation of populations of cardiac-derived stem cells and 
progenitor cells. (80) 
 
 
heart failure ensues on a more macro scale. This is a crucial piece of the puzzle, 
as all current treatment modalities for those in heart failure do not actually heal or 
restore the ability of the cardiomyocytes to function properly, with the exception 
of cardiac transplantation. Cardiac stem cell therapy would therefore be the first 
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therapy capable of transforming dead or deleteriously remodeled tissue into 
physiologically active, functioning myocardium allowing medical professionals to 
prevent or even reverse the pathophysiology of heart failure (94).  
 While there is little argument with respect to the potential that cardiac stem 
cell therapy may have on the field of medicine, creating a therapy that would be 
effective and safe clinically has proven much more challenging than originally 
thought. In addition to the various obstacles of creating an effective therapy, the 
discovery of so many different cell types that may serve as candidates for stem 
cell therapy expands the work load of scientists as they attempt evaluate which 
would prove most beneficial. Such a vast spectrum of cell types also points to the 
significant lack of mechanistic understanding of cell-based therapies at many 
levels (94). In fact, there have been very few studies that have done any sort of 
comparison between the various cell types to decipher which have the greatest 
potential for a cell based therapy, as to focus time and resources on those more 
qualified candidates (95).  
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Figure 16: Depiction of the Various Mechanisms and Barriers to Stem Cell 
Therapy and Cardiac Regeneration (94) 
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The Current Status of a Cell-Based Therapy for Heart Failure 
 It has now been established that the human adult heart contains a 
population of cardiac stem cells that are self renewing and possess the capacity 
to differentiate into all three major cardiac cell lineages; myocytes, vascular 
smooth muscle cells, and endothelial cells (96). Over the last decade, research 
has shown that the transplantation of these cells into a failing heart of an animal 
model attenuates pathologic left ventricular remodeling and improves the 
efficiency and function of the left ventricle that had previously experienced a 
myocardial infarct (79). While these findings are undoubtedly encouraging, very 
little has been done with respect to regenerating a human heart.  
 In 2011, one of the first phase one human trials was undertaken, the 
SCIPIO (cardiac stem cells in patients with ischemic cardiomyopathy) study, 
evaluated the effect of intracoronary infusion of autologous cardiac stem cells in 
improving left ventricular systolic function and reducing the infarct size in patients 
with heart failure as the result of a myocardial infarction, and if further 
investigation in the form of a phase two trial is warranted for this therapy (97). 
The results of the SCIPIO study suggest that in fact cardiac stem cells can be 
reproducibly isolated and expanded from approximately one gram of myocardial 
tissue that can be harvested during cardiac surgery. They found that patients 
who received infusions of cardiac stem cells showed marked improvement in left 
ventricle systolic function at four months post-infusion compared to patients who 
did not receive the cardiac stem cells, and an even greater improvement in LV 
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systolic function one year following infusion of CSCs. After one year of follow up, 
it was observed that the patients who received stem cell therapy had not only a 
significantly improved LV systolic function, but also an increased functional 
capacity, improved quality of life, and reduction in the size of the scar that 
resulted from the myocardial infarct (97). Ultimately, the SCIPIO study provided 
strong rationale for further studies into the use of cardiac stem cell therapies for 
patients in severe heart failure with a poor prognosis.  
 To date, there have been several studies that have examined the effects 
of cardiac stem cells on improving LV systolic function and improving outcomes 
in patients with severe heart failure. These studies have had very small study 
populations and used a variety of stem cell types delivered either intracoronary 
transendocardial, as well as differing with respect to number and volume of stem 
cells delivered, timing and processing, and whether or not adjunctive therapy was 
used (98). Some of these studies have shown significant improvements in LV 
systolic function and a reversal of pathologic remodeling, while others observed 
no significant difference between those who received no therapy at all. 
Interestingly, a few studies have even shown that evidence that the control 
group, those who did not receive stem cell therapy, exhibited slight 
improvements in cardiac function over time (99,100).  
 While these studies did show that the use of cardiac stem cell therapy is 
safe and not likely to result in adverse outcomes directly related to CSC therapy, 
they have been unable to consistently show that the therapy has the ability to 
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regenerate a failing ventricle. However, they have provided valuable insight into 
the many challenges that stand in the way of a truly effective CSC therapy, and 
brought to our attention the most significant hurdles that must be overcome to 
attain the ultimate long-term goal of true myocardial regeneration. The two most 
important barriers at present are providing the right environment into which the 
stem cells can be infused, and the specific nature of the cells utilized. Additional, 
and also noteworthy barriers that current research is aiming to address are 
improving the survival of the injected stem cells, increasing their persistence at 
the site of injection, and expanding their capacity to proliferate once introduced 
into the tissue (98).  
 
 
 
 
Figure 17: The Challenges of a Clinically Acceptable Stem Cell Therapy (94) 
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Conclusions and the Future of Treating Heart Failure 
 It is clear that heart failure is a significant public health concern with an 
ever-increasing prevalence in most developed countries worldwide. Such an 
increase is thought to be primarily the result of three things. First, advances in 
medical technology over the last few decades have allowed a far greater number 
of patients to survive acute coronary artery disease, myocardial infarctions, and 
acute decompensated heart failure. As these cardiac events often serve as the 
initial insult in the heart failure sequelae, these surviving patients now go on to 
develop chronic heart failure. Second, improvements in the treatment of those 
with chronic heart failure have increased the time one can live with the chronic 
disease. Finally, the U.S. population as a whole is not only exponentially growing, 
but also aging. Because advanced age is significantly associated with heart 
failure, the increasing aging population inevitably results in an increase in the 
number of people being diagnosed with HF (5). In addition, the management and 
treatment of heart failure costs the U.S. health care system more than 30 billion 
dollars a year (3), adding immense financial strain to a health care system 
significantly struggling to control costs. It is therefore critical that much attention 
be given to this growing epidemic at present and well into the future.  
 Because there is currently no treatment for reversing the pathologic 
remodeling of heart failure, once a patient develops HF, it is only a matter of time 
before they progress to late stage failure. For these patients, the best available 
treatment option is cardiac transplantation where they receive a healthy donor 
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heart. Unfortunately, the number of patients on the list for a donor organ far 
outweighs the number of hearts available for transplant. Mechanical Circulatory 
Support is the next best option for those that are not able to undergo 
transplantation. Specifically, ventricular assist devices are recommended for 
these patients, although they are not without significant risk (14). According to 
the INTERMACS database, the number of assist devices implanted has 
increased from 352 in 2007 to 2,217 in 2012. As the number of assist device 
implantations continues to rise, so will the number of patients with adverse 
events. It is therefore critical that much attention be allocated to treating or 
reducing the spectrum of adverse events that accompany current ventricular 
assist devices. 
 The most current ventricular assist devices are a significant improvement 
from their predecessors. Not only can they produce a significant volume output 
allowing them to significantly alleviate volume and pressure overload in the 
ventricles, but they have also reduced the likelihood of adverse outcomes as a 
direct result of the VAD (16). The biggest obstacle that accompanies current VAD 
technology is their non-biological nature. Not only is mechanical failure a 
significant risk with many VADs, but also the pump aspect of the device has a 
high propensity to form thrombi. It is crucial that future models of VADs reduce 
the risk of thrombus formation and infection, as well as increasing the duration 
that they can provide circulatory support.  
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 No matter how advanced ventricular assist devices become, they will 
never possess the ability to regenerate the hearts ability to effectively function on 
its own. They also will always have a risk of adverse events because they will 
always be foreign to normal physiology. The only treatment option with the 
potential to regenerate the native myocardium, excluding cardiac transplantation, 
is cardiac stem cell therapy. While there will be a place for highly efficient assist 
devices in the practice of medicine, cardiac stem cell therapy is the only 
treatment modality with the potential to truly solve the heart failure epidemic.  
 The future of cardiac stem cell therapy and its ability to provide myocardial 
regeneration remains bright. However, there is still much work to be done before 
an effective therapy will be available for clinical use. Over the next several years, 
it is crucial that researchers determine the specific environmental characteristics 
that will provide the stem cells the greatest probability to persist within the 
intended tissue and allow them to effectively proliferate. It is likely that these 
modifications to the cell environment will be aimed at reducing the expression of 
inflammatory cytokines that are released as a result of injury to the myocardium 
during the infarct. A reduction in the expression of these inflammatory cytokines, 
such as tumor necrosis factor (TNF-α), interleukins (ILs), matrix 
metalloproteinases, and transforming growth factor-β (TGF-β), will reduce the 
pro-apoptotic influence on the infused stem cells, thus improving their survival 
(101). Other proposed methods of improving the survival of cardiac stem cells 
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are to precondition the cells prior to injection, or to genetically modify the cells to 
ensure improved survival (98).  
 More important still is the question of which type of stem cell or progenitor 
cell is the best candidate for a clinical therapy (95).  In order to make this 
distinction, we must first attain a thorough understanding of the specific 
mechanisms by which each type of stem or progenitor cell influences the 
physiology of the myocardium (102). This will likely prove to be a pivotal piece to 
the stem cell therapy puzzle, because there is a strong possibility that different 
types of cardiac pathologies will require different cell types. By further expanding 
our knowledge of the complexities that underlie cardiac regeneration, we will 
move toward the possibility of creating a therapy that can be infused into a 
diseased heart, triggering a complete reversal of pathologic remodeling while 
returning the diseased heart to a healthy functioning state.  
To take stem cell technology and regeneration one step further is to 
consider the possibility of creating or growing an entire organ, such as a heart, in 
vitro, from the patients own cell lines. This organ could then be transplanted into 
patients who have suffered catastrophic injury to their heart, or who are so 
severely diseased that the “traditional” stem cell therapy would likely not work 
quickly enough. Because the lab grown tissue is composed of the patient’s own 
cells, intense immunosuppressant therapy would no longer be necessary. As the 
population continues to grow, the number of people with heart failure is likely rise 
to an extraordinary level. With the number of donor hearts available for 
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transplantation ever dwindling, the ability to grow a complete organ in the lab that 
can then be transplanted into the severely ill patient would undoubtedly save 
millions of lives, impacting billions of people worldwide.  
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